Survivin, an inhibitor of apoptosis protein (IAP) family member, is expressed during fetal development and was reported to be undetectable in terminally differentiated adult tissues. 1 More recent studies have shown that survivin expression is also high in immature bone marrow neutrophil precursors and can be detected in terminally differentiated neutrophils from patients with chronic inflammation. 2 Survivin is also prominently expressed in most common cancers and is associated with chemoresistance and poor prognosis, making survivin-targeted therapies an attractive cancer treatment strategy. 1, 3 Severe congenital neutropenia (SCN) is a heterogenous group of primary immunodeficiencies in which a lack of neutrophils causes inadequate immune responses to bacterial infections. Patients suffering from autosomal recessive SCN (also known as Kostmann disease) display a characteristic maturation arrest at the promyelocyte/myelocyte stage of myelopoiesis, and our previous studies have demonstrated that this maturation arrest is associated with mitochondria-dependent apoptosis of myeloid progenitor cells. 4 Moreover, recent studies have identified homozygous mutations in the antiapoptotic gene encoding HAX-1 in patients with Kostmann disease, including patients belonging to the original kindred described by Rolf Kostmann in northern Sweden.
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Lymphoid enhancer-binding factor-1 is a transcription factor that has been implicated in the proliferation, survival and differentiation of neutrophil progenitors. A previous study has shown that the expression of lymphoid enhancer-binding factor-1 is diminished or even absent in the bone marrow of SCN patients with a classical maturation arrest of the myelopoiesis. 6 Of considerable interest, expression of the lymphoid enhancer-binding factor-1 target gene, survivin, was also shown to be defective in myeloid precursors from SCN patients. On the basis of these findings, defective survivin expression was proposed to be one of the key events underlying the enhanced apoptosis of myeloid progenitors in SCN patients. 6 However, survivin expression was not assessed at the protein level in these studies. To further our understanding of the potential role of survivin in SCN, we performed a semiquantitative assessment of survivin protein expression in the bone marrow of 6 SCN patients, including three patients belonging to the original Kostmann family. Patient characteristics are reported in Table 1 . Homozygous HAX1 mutations were identified in two patients, and ELA2 mutations in three patients, and in one patient the gene defect remains unknown (mutations in HAX1 and ELA2 were excluded in this individual).
Increased survivin expression in myeloid precursors was detected to various degrees in bone marrow biopsies of all SCN patients in comparison to reactive bone marrow, irrespective of the underlying genetic defect (Figure 1a-c) . SCN patients are at an increased risk of evolution to myelodysplastic syndrome/ acute myeloid leukemia (MDS/AML), and we were interested to study the expression of survivin in SCN patients who develop secondary malignancies. We had the opportunity to evaluate survivin expression in one patient belonging to the original Swedish Kostmann kindred before and during the evolution of acute lymphoblastic leukemia (ALL). In contrast to our expectations, survivin expression was markedly decreased at the time of diagnosis of ALL (Table 1) . Moreover, our evaluation of 10 patients with leukemia/lymphoma failed to reveal any significant expression of survivin in the bone marrow (as exemplified by Figure 1f , and data not shown). On the other hand, survivin expression in the SCN patients studied herein appeared to correlate with the dose of recombinant granulocyte colonystimulating factor (G-CSF), as reported in Table 1 .
Severe congenital neutropenia patients receive daily injections of G-CSF and this treatment cannot be interrupted for a prolonged period due to the risk of low absolute neutrophil count values and subsequent infections. Therefore, to further address whether survivin expression can be related to G-CSF treatment, we studied survivin expression in a pediatric patient with rhabdomyosarcoma without bone marrow involvement before and after treatment with recombinant G-CSF (dose: 5 mg/ kg/day). Notably, survivin expression was induced in the bone marrow following G-CSF treatment (Figure 1d and e) , although the numbers of survivin-positive myeloid precursors were lower than in SCN patients. Nevertheless, these findings are in line with previous in vitro studies demonstrating the re-expression of survivin in normal neutrophils and hematopoietic stem cells following incubation with recombinant growth factors, including G-CSF. 2, 7 For comparison, studies in leukemia-derived cell lines and primary AML cells have also provided evidence that hematopoietic cytokines may exert their effects by increasing Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ANC, absolute neutrophil count; BM, bone marrow; G-CSF, granulocyte colony-stimulating factor; GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplant; Nd, no data available; SCN, severe congenital neutropenia. a All SCN patients are subjected to examination of the BM on an annual basis due to the risk of developing secondary malignancies. For some patients, BM samples were evaluated for survivin expression at more than one time point, as indicated. Ethical permission to conduct the current study was granted by the Ethical Review Committee at Karolinska Institutet. Semiquantitative assessment was performed on the basis of paraffin sections of BM biopsies, as described in the legend of Figure 1 .
Letters to the Editor survivin expression. 8 Furthermore, our previous studies showed that Bcl-2 expression was reduced in the bone marrow of Kostmann patients at the time of diagnosis, but its expression was restored upon initiation of G-CSF treatment. 4 Therefore, the well-documented therapeutic effect of G-CSF in Kostmann disease patients may be explained, at least in part, by the induction of both Bcl-2 and survivin, each acting in a distinct yet complementary manner to suppress apoptosis in myeloid Figure 1 Immunohistochemical detection of antiapoptotic survivin expression in bone marrow biopsies from severe congenital neutropenia (SCN) patients and controls. Immunostaining was performed on paraffin sections from bone marrow biopsies using an antisurvivin rabbit polyclonal antibody from LAB VISION (Freemont, CA, USA) and the Ventana automated staining system. (a) Staining pattern in normal reactive bone marrow. Single cells with cytoplasmic survivin expression were noted ( Â 200) (corresponding to semiquantitative level 1; see Table 1 progenitors, thereby compensating for the inherited loss of antiapoptotic HAX-1. It could be pertinent to study the expression of survivin in the bone marrow of other patients with inherited or acquired neutropenia, with or without recombinant growth factor treatment.
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults, but the fundamental genetic abnormalities underlying this disease remain elusive. The clinical course is variable with a survival ranging from 2 to more than 15 years. Many clinical (for example, stage and lymphocyte doubling time) and biological (for example, mutational status, CD38, ZAP-70 expression) factors are known to predict clinical outcome. The strongest single predictor is a deletion of chromosome 17p13, 1,2 involving TP53, a tumor suppressor gene that is involved in cell cycling and cell death. 3 This deletion is found in approximately 7% of CLL patients and is associated with a refractory response to chemotherapy and a median survival of only 32 months. 1, 2 MicroRNAs are small non-coding RNAs that regulate the translation of protein-coding mRNAs and thereby protein expression. Numerous microRNAs have been linked with human disease and cancer. Recently, it has been shown in several studies that microRNA-34 is a direct transcriptional target of TP53 and that microRNA-34 downregulates the expression of several TP53 downstream targets. Furthermore, microRNA-34 has found to be downregulated in several types of cancer. 4, 5 In this study, we hypothesized that 17p13/TP53 deletion in patients with CLL is associated with the decreased microRNA-34 expression.
Chronic lymphocytic leukemia patients were clinically diagnosed according to the World Health Organization criteria. 6 Twenty-six patients were selected based on 17p13/TP53 deletion status (Table 1) , as determined by the interphase fluorescence in situ hybridization analysis using a commercially available DNA probe LSI p53 (Vysis, Downers Grove, IL, USA). Total RNA of cryopreserved peripheral blood mononuclear cells was extracted using Trizol reagent according to manufacturer's protocol (Invitrogen, Breda, The Netherlands). Quality control of RNA was done using RNA 6000 Nano assay on the Agilent 2100 Bioanalyser (Agilent, Palo Alto, CA, USA), and all RNA samples showed high quality. Quantitative RT-PCR for mature microRNAs was performed as described by the manufacturer (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). Small nucleolar RNAs (RNU24 and RNU66) were used for normalization and relative expression levels, and were determined using the 2 ÀDDCt method (compared with an average expression level of the patients without TP53 deletion).
